Rituximab is highly effective for pure red cell aplasia and post-transplant lymphoproliferative disorder after unrelated hematopoietic stem cell transplantation

Rituximab is highly effective for pure red cell aplasia and post-transplant lymphoproliferative disorder after unrelated hematopoietic stem cell transplantation

Pure red cell aplasia (PRCA) and post-transplant lymphoproliferative disorder (PTLD) constitute rare complications after allogeneic hematopoietic stem cell transplantation (AlloHSCT). The incidence of EBV-PTLD is above 1%, but it may increase in patients with well-known risk factors such as EBV sero...

Full description

Bibliographic Details
Main Authors: Kopińska, Anna, Helbig, Grzegorz, Frankiewicz, Andrzej, Grygoruk-Wiśniowska, Iwona, Kyrcz-Krzemień, Sławomira
Format: Online
Language:English
Published: Termedia Publishing House 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687412/

Similar Items

Similar Items